<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cy--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16175188</article-id><article-id pub-id-type="pmc">2361637</article-id><article-id pub-id-type="pii">6602760</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6602760</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Maisey</surname><given-names>N R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Norman</surname><given-names>A R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Massey</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Oates</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:ProfDavid.Cunningham@rmh.nhs.uk">ProfDavid.Cunningham@rmh.nhs.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>09</month><year>2005</year></pub-date><pub-date pub-type="collection"><day>27</day><month>09</month><year>2005</year></pub-date><pub-date pub-type="ppub"><day>03</day><month>10</month><year>2005</year></pub-date><volume>93</volume><issue>7</issue><fpage>740</fpage><lpage>743</lpage><history><date date-type="received"><day>02</day><month>03</month><year>2005</year></date><date date-type="rev-recd"><day>01</day><month>08</month><year>2005</year></date><date date-type="accepted"><day>02</day><month>08</month><year>2005</year></date></history><copyright-statement>Copyright 2005, Cancer Research UK</copyright-statement><copyright-year>2005</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95&#x00025; CI: 1.3&#x02013;2.5, <italic>P</italic>&#x0003d;0.0004). The 1-year OS was 19 and 46&#x00025;, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20&#x00025; in CA19-9 level from baseline was an independent prognostic factor for OS (HR 1.9; 95&#x00025; CI: 1.1&#x02013;3.4, <italic>P</italic>&#x0003d;0.019).</p></abstract><kwd-group><kwd>pancreatic cancer</kwd><kwd>CA19-9</kwd><kwd>prognosis</kwd><kwd>chemotherapy</kwd></kwd-group></article-meta></front><body><p>Over the last decade, systemic chemotherapy has become a standard therapy for patients with inoperable pancreatic cancer. Prior to this, the lack of randomised data and the perceived toxicity of treatment led most clinicians to believe that cytotoxic therapy would not be of palliative benefit or could significantly prolong their patients' lives. Following a number of randomised clinical trials, it became clear that not only did chemotherapy offer a small but significant survival benefit, but there was also evidence supporting an improvement in quality of life. Over the last decade, a number of relatively large and well-conducted phase III trials have attempted to define the optimal chemotherapy schedule for this cohort of patients. Currently, the standard of care is gemcitabine, following the seminal paper by <xref ref-type="other" rid="bib2">Burris <italic>et al</italic> (1997)</xref>. A number of ongoing trials are exploring the potential benefit of gemcitabine scheduling, combination with other chemotherapeutic agents and the addition of novel agents such as antibodies to the epidermal growth factor receptor and vascular endothelial growth factor.</p><p>In the mid 1990s, the CONSORT (Consolidated Standards of Reporting Trials) statement was published, which was intended to improve the quality of reporting of phase III trials (<xref ref-type="other" rid="bib10">Moher <italic>et al</italic>, 2001</xref>). The CONSORT statement consists of a checklist and a diagram intended for use in writing, reviewing or assessing reports of randomised controlled trials. One of the items in the checklist is the reporting of baseline demographic and clinical characteristics of each group.</p><p>When assessing the results of a phase III trial, it is clearly vital that the known important prognostic factors are balanced between treatment arms to allow a fair comparison of treatment effect. Despite a small number of publications suggesting that the tumour marker CA19-9 is an important prognostic variable (<xref ref-type="other" rid="bib5">Gogas <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib6">Halm <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib15">Saad <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib16">Stemmler <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib18">Ziske <italic>et al</italic>, 2003</xref>), none of the large published randomised studies of chemotherapy to date have reported baseline CA19-9 levels.</p><p>The aim of this retrospective analysis was to investigate whether CA19-9 provided prognostic information in patients with inoperable pancreatic cancer treated with systemic chemotherapy, and should therefore be reported in future randomised controlled trials.</p><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><p>All patients treated with gemcitabine- and&#x0002f;or 5-fluorouracil-based chemotherapy in three consecutive phase III randomised trials at this centre were eligible for analysis. Patients had inoperable or metastatic histologically proven pancreatic cancer, were of WHO performance status (PS) 0&#x02013;2 and had radiologically measurable disease. All patients were previously untreated. Entry criteria included a total serum bilirubin level of 30&#x02009;<italic>&#x003bc;</italic>mol&#x02009;l<sup>&#x02212;1</sup> or less. Informed written consent was obtained from all patients.</p><sec><title>Treatment</title><p>All eligible patients received one of four chemotherapy regimens. Protracted venous infused 5-fluorouracil (PVI 5FU) was either given alone (at a dose of 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> for a maximum of 24 weeks) or in combination with mitomycin C (MMC) administered at a dose of 7&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> 6 weekly for four courses. The remainder received a combination of gemcitabine (1000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> on days 1, 8 and 15 of a 28-day cycle) and capecitabine (830&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> twice daily for 21 days followed by a week's break) or gemcitabine alone, at a dose of 1000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> weekly for 7 weeks, followed by a week's break and subsequently for 3 weeks out of every 4.</p></sec><sec><title>Measurements</title><p>Serum CA19-9 was measured at baseline (defined as being within 30 days before the start of chemotherapy) and subsequently every 6 weeks while the patients remained on treatment. The CA19-9 concentration was measured by an automated, commercially available enzyme immunoassay on an axsym analyser (Abbott Diagnostics Laboratory). A value of 37&#x02009;U&#x02009;ml<sup>&#x02212;1</sup> was used as the upper limit of normal.</p></sec><sec><title>Statistics</title><p>All data were recorded prospectively on the Gl unit database. Overall survival (OS) (defined as time from randomisation to death from any cause) was examined with the Kaplan&#x02013;Meier product limit method (<xref ref-type="other" rid="bib7">Kaplan and Meier, 1958</xref>), and survival in patients with baseline CA19-9 values that fell above or below the median level (median dichotomised) was compared with the log-rank test (<xref ref-type="other" rid="bib12">Peto and Peto, 1972</xref>). Statistical analysis was performed using the statistical package SPSS for Windows version 12.01. Multivariate logistic regression was used to determine factors predictive of survival. Factors included in these analyses were baseline CA19-9, a 20&#x00025; drop in CA19-9 level following the start of chemotherapy, age, sex, the presence of locally advanced or metastatic disease and performance status. A fall of 20&#x00025; in the CA19-9 level was chosen after review of similar analyses in the literature. <italic>P</italic>-values of less than 0.05 were considered statistically significant.</p></sec></sec><sec><title>RESULTS</title><sec><title>Patients</title><p>Between July 1994 and July 2004, 218 patients received chemotherapy in the context of a clinical trial. Of these patients, 154 had a CA19-9 level recorded within 30 days before the start of chemotherapy at this centre. Baseline demographics are given in <xref rid="tbl1" ref-type="table">Table 1</xref>.</p></sec><sec><title>CA19-9 levels</title><p>Baseline CA19-9 levels were recorded in 154 patients. The median time of performing the test was 1 day prior to the start of chemotherapy (range 0&#x02013;30). The median baseline CA19-9 level was 958&#x02009;U&#x02009;ml<sup>&#x02212;1</sup>.</p><p>Post-treatment CA19-9 was recorded in 88 patients. The median time of performing the test from the start of chemotherapy was 42 days, ranging from 28 to 55 days. The median post-treatment CA19-9 level was 998&#x02009;U&#x02009;ml<sup>&#x02212;1</sup>. There was no significant difference in the time to progression (TTP) between the cohort that had CA19-9 levels performed at baseline and following chemotherapy, compared with the cohort that had baseline levels only (<italic>P</italic>&#x0003d;0.46).</p></sec><sec><title>Survival</title><p>The median follow-up in those patients with a recorded baseline CA19-9 level was 712 days and 92&#x00025; had died at the time of analysis. The median OS in patients with a baseline CA19-9 below the median value was significantly superior to those with a value above (337 <italic>vs</italic> 165 days, <italic>P</italic>&#x0003d;0.0004). The 1-year OS was 19 and 46&#x00025;, respectively, for patients with a baseline CA19-9 above or below the median value (see <xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>In a multivariate analysis, baseline CA19-9 above or below the median value (958&#x02009;U&#x02009;ml<sup>&#x02212;1</sup>) was found to be an independent prognostic factor for OS (HR 1.8; 95&#x00025; CI: 1.3&#x02013;2.5, <italic>P</italic>&#x0003d;0.0004).</p><p>A fall of 20&#x00025; in CA19-9 level at first measurement following the start of treatment was an independent prognostic factor for OS (HR 1.9; 95&#x00025; CI: 1.1&#x02013;3.4, <italic>P</italic>&#x0003d;0.019). Baseline characteristics in this group were not significantly different from the original cohort.</p><p>Other factors that were found to be independent prognostic factors for OS were sex and performance status (PS) (see <xref rid="tbl2" ref-type="table">Table 2</xref>).</p></sec></sec><sec><title>DISCUSSION</title><p>Ensuring an equal balance of prognostic factors between treatment arms in randomised controlled trials is vital. This may be particularly relevant when the clinical benefit of an intervention is likely to be small, as is the case for patients with advanced pancreatic cancer. A number of both patient- and disease-related factors have been identified as independent prognostic markers, including PS, sex and the presence of metastases, and are routinely quoted in clinical studies as baseline characteristics. There have also been several reports of various biological markers that may carry some prognostic significance. These include growth factors such as vascular endothelial growth factor and platelet-derived endothelial cell growth factor (<xref ref-type="other" rid="bib3">Fujimoto <italic>et al</italic>, 1998</xref>), microsatellite instability (<xref ref-type="other" rid="bib11">Nakata <italic>et al</italic>, 2002</xref>), tumour suppression gene expression such as SMAD4 (<xref ref-type="other" rid="bib1">Biankin <italic>et al</italic>, 2002</xref>) and the expression of mutated genes controlling response to DNA damage, such as GADD45a and p53 (<xref ref-type="other" rid="bib17">Yamasawa <italic>et al</italic>, 2002</xref>).</p><p>The serum carbohydrate antigen CA19-9 is a tumour-associated antigen that has been shown to be a highly specific and sensitive serum marker for pancreatic cancer (<xref ref-type="other" rid="bib13">Pleskow <italic>et al</italic>, 1989</xref>; <xref ref-type="other" rid="bib14">Rollhauser and Steinberg, 1998</xref>). CA19-9 is a sialylated Lewis blood group antigen targeted by the monoclonal antibody 1116 NS 19-9 (<xref ref-type="other" rid="bib9">Koprowski <italic>et al</italic>, 1979</xref>). Previous studies have demonstrated a prognostic role for pretreatment CA19-9 in patients receiving radiotherapy (<xref ref-type="other" rid="bib8">Katz <italic>et al</italic>, 1998</xref>) or undergoing pancreatic resection (<xref ref-type="other" rid="bib4">Glenn <italic>et al</italic>, 1988</xref>). Although a small number of papers have described a fall in CA19-9 to be an independent prognostic variable for survival (<xref ref-type="other" rid="bib5">Gogas <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib15">Saad <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib16">Stemmler <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib18">Ziske <italic>et al</italic>, 2003</xref>), there have been surprisingly few studies investigating the use of baseline CA19-9 in predicting survival for patients with inoperable pancreatic cancer who undergo systemic chemotherapy. <xref ref-type="other" rid="bib6">Halm <italic>et al</italic> (2000)</xref> reported the survival of 43 consecutive patients with advanced pancreatic cancer treated with single-agent gemcitabine. In a multivariate analysis, baseline CA19-9 was reported to be an independent prognostic predictor of survival with a relative risk of death 1.4 (95&#x00025; CI: 1.0&#x02013;2.0, <italic>P</italic>&#x0003d;0.04). <xref ref-type="other" rid="bib18">Ziske <italic>et al</italic> (2003)</xref> published their results in a similar cohort of patients (<italic>n</italic>&#x0003d;46). Although they did not report baseline CA19-9 level as a prognostic variable, they did find that a fall of at least 20&#x00025; in CA19-9 level following the start of chemotherapy was the only independent prognostic marker for OS in their Cox multivariate analysis. An important caveat in the interpretation of CA19-9 levels in pancreatic cancer is the presence of biliary obstruction, which results in the elevation of the marker level. In the current series, however, entry criteria mandated that serum bilirubin should be 30&#x02009;<italic>&#x003bc;</italic>mol&#x02009;l<sup>&#x02212;1</sup> or less, and therefore this potential pitfall was avoided in the interpretation of baseline CA19-9 levels.</p><p>The results of this study suggest that baseline tumour marker CA19-9 is an important independent prognostic variable in patients with inoperable pancreatic cancer. We found that baseline CA19-9 above or below the median value (958&#x02009;U&#x02009;ml<sup>&#x02212;1</sup>) was an independent prognostic factor for OS (HR 1.8; 95&#x00025; CI: 1.3&#x02013;2.5, <italic>P</italic>&#x0003d;0.0004), with a 1-year OS of 19 and 46&#x00025;, respectively. Although this is the largest reported series examining the predictive value of baseline CA19-9 in patients treated with systemic chemotherapy, it is still a relatively small cohort of 154 patients, and further studies would be welcome to consolidate these results. However, considering its apparent prognostic value, future randomised controlled trials should consider reporting median CA19-9 levels in treatment groups as part of routine demographic data.</p></sec></body><back><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Morey</surname><given-names>AL</given-names></name><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Kench</surname><given-names>JG</given-names></name><name><surname>Biankin</surname><given-names>SA</given-names></name><name><surname>Hook</surname><given-names>HC</given-names></name><name><surname>Head</surname><given-names>DR</given-names></name><name><surname>Hugh</surname><given-names>TB</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><name><surname>Henshall</surname><given-names>SM</given-names></name></person-group><article-title>DPC4&#x0002f;Smad4 expression and outcome in pancreatic ductal adenocarcinoma</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>4531</fpage><lpage>4542</lpage><!--PubMed citation query: 'J Clin Oncol||20|4531||bib1|'--><pub-id pub-id-type="pmid">12454109</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burris</surname><given-names>HA</given-names><suffix>3rd</suffix></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Modiano</surname><given-names>MR</given-names></name><name><surname>Cripps</surname><given-names>MC</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name><name><surname>Stomiolo</surname><given-names>AM</given-names></name><name><surname>Tarassoff</surname><given-names>P</given-names></name><name><surname>Nelson</surname><given-names>R</given-names></name><name><surname>Dorr</surname><given-names>FA</given-names></name><name><surname>Stephens</surname><given-names>CD</given-names></name><name><surname>Von Hoff</surname><given-names>DD</given-names></name></person-group><article-title>Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>2403</fpage><lpage>2413</lpage><!--PubMed citation query: 'J Clin Oncol||15|2403||bib2|'--><pub-id pub-id-type="pmid">9196156</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Hosotani</surname><given-names>R</given-names></name><name><surname>Wada</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>JU</given-names></name><name><surname>Koshiba</surname><given-names>T</given-names></name><name><surname>Miyamoto</surname><given-names>Y</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Nakajima</surname><given-names>S</given-names></name><name><surname>Doi</surname><given-names>R</given-names></name><name><surname>Imamura</surname><given-names>M</given-names></name></person-group><article-title>Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis</article-title><source>Eur J Cancer</source><year>1998</year><volume>34</volume><fpage>1439</fpage><lpage>1447</lpage><!--PubMed citation query: 'Eur J Cancer||34|1439||bib3|'--><pub-id pub-id-type="pmid">9849429</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glenn</surname><given-names>J</given-names></name><name><surname>Steinberg</surname><given-names>WM</given-names></name><name><surname>Kurtzman</surname><given-names>SH</given-names></name><name><surname>Steinberg</surname><given-names>SM</given-names></name><name><surname>Sindelar</surname><given-names>WF</given-names></name></person-group><article-title>Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas</article-title><source>J Clin Oncol</source><year>1988</year><volume>6</volume><fpage>462</fpage><lpage>468</lpage><!--PubMed citation query: 'J Clin Oncol||6|462||bib4|'--><pub-id pub-id-type="pmid">3162513</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gogas</surname><given-names>H</given-names></name><name><surname>Lofts</surname><given-names>FJ</given-names></name><name><surname>Evans</surname><given-names>TR</given-names></name><name><surname>Daryanani</surname><given-names>S</given-names></name><name><surname>Mansi</surname><given-names>JL</given-names></name></person-group><article-title>Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>325</fpage><lpage>328</lpage><!--PubMed citation query: 'Br J Cancer||77|325||bib5|'--><pub-id pub-id-type="pmid">9461005</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halm</surname><given-names>U</given-names></name><name><surname>Schumann</surname><given-names>T</given-names></name><name><surname>Schiefke</surname><given-names>I</given-names></name><name><surname>Witzigmann</surname><given-names>H</given-names></name><name><surname>Mossner</surname><given-names>J</given-names></name><name><surname>Keim</surname><given-names>V</given-names></name></person-group><article-title>Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer</article-title><source>Br J Cancer</source><year>2000</year><volume>82</volume><fpage>1013</fpage><lpage>1016</lpage><!--PubMed citation query: 'Br J Cancer||82|1013||bib6|'--><pub-id pub-id-type="pmid">10737382</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>EL</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name></person-group><article-title>Non parametric estimation from incomplete observations</article-title><source>J Am Stat Assoc</source><year>1958</year><volume>53</volume><fpage>457</fpage><lpage>481</lpage><!--PubMed citation query: 'J Am Stat Assoc||53|457||bib7|'--></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>A</given-names></name><name><surname>Hanlon</surname><given-names>A</given-names></name><name><surname>Lanciano</surname><given-names>R</given-names></name><name><surname>Hoffman</surname><given-names>J</given-names></name><name><surname>Coia</surname><given-names>L</given-names></name></person-group><article-title>Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1998</year><volume>41</volume><fpage>393</fpage><lpage>396</lpage><!--PubMed citation query: 'Int J Radiat Oncol Biol Phys||41|393||bib8|'--><pub-id pub-id-type="pmid">9607356</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koprowski</surname><given-names>H</given-names></name><name><surname>Steplewski</surname><given-names>Z</given-names></name><name><surname>Mitchell</surname><given-names>K</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Heriyn</surname><given-names>D</given-names></name><name><surname>Fulner</surname><given-names>P</given-names></name></person-group><article-title>Colorectal carcinoma antigens detected by hybridoma antibodies</article-title><source>Somatic Cell Genet</source><year>1979</year><volume>5</volume><fpage>957</fpage><lpage>971</lpage><!--PubMed citation query: 'Somatic Cell Genet||5|957||bib9|'--><pub-id pub-id-type="pmid">94699</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>1191</fpage><lpage>1194</lpage><!--PubMed citation query: 'Lancet||357|1191||bib10|'--><pub-id pub-id-type="pmid">11323066</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakata</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>YQ</given-names></name><name><surname>Yashiro</surname><given-names>M</given-names></name><name><surname>Nishioka</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Ohira</surname><given-names>M</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Nishino</surname><given-names>H</given-names></name><name><surname>Hirakawa</surname><given-names>K</given-names></name></person-group><article-title>Prognostic value of microsatellite instability in resectable pancreatic cancer</article-title><source>Clin Cancer Res</source><year>2002</year><volume>8</volume><fpage>2536</fpage><lpage>2540</lpage><!--PubMed citation query: 'Clin Cancer Res||8|2536||bib11|'--><pub-id pub-id-type="pmid">12171881</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peto</surname><given-names>R</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name></person-group><article-title>Asymtolically efficient invariant procedures</article-title><source>J R Stat Soc</source><year>1972</year><volume>A135</volume><fpage>185</fpage><lpage>206</lpage><!--PubMed citation query: 'J R Stat Soc||A135|185||bib12|'--></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pleskow</surname><given-names>DK</given-names></name><name><surname>Berger</surname><given-names>HJ</given-names></name><name><surname>Gyves</surname><given-names>J</given-names></name><name><surname>Allen</surname><given-names>E</given-names></name><name><surname>McLean</surname><given-names>A</given-names></name><name><surname>Podolsky</surname><given-names>DK</given-names></name></person-group><article-title>Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer</article-title><source>Ann Intern Med</source><year>1989</year><volume>110</volume><fpage>704</fpage><lpage>709</lpage><!--PubMed citation query: 'Ann Intern Med||110|704||bib13|'--><pub-id pub-id-type="pmid">2930108</pub-id></citation></ref><ref id="bib14"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Rollhauser</surname><given-names>C</given-names></name><name><surname>Steinberg</surname><given-names>W</given-names></name></person-group><article-title>Tumor antigens in pancreatic cancer</article-title><source>Pancreatic Cancer</source><year>1998</year><publisher-name>Totowa, NJ: Humana Press</publisher-name><fpage>137</fpage><lpage>156</lpage>Reber HA (ed) pp</citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saad</surname><given-names>ED</given-names></name><name><surname>Machado</surname><given-names>MC</given-names></name><name><surname>Wajsbrot</surname><given-names>D</given-names></name><name><surname>Abramoff</surname><given-names>R</given-names></name><name><surname>Hoff</surname><given-names>PM</given-names></name><name><surname>Tabacof</surname><given-names>J</given-names></name><name><surname>Katz</surname><given-names>A</given-names></name><name><surname>Simon</surname><given-names>SD</given-names></name><name><surname>Gansl</surname><given-names>RC</given-names></name></person-group><article-title>Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine</article-title><source>Int J Gastrointest Cancer</source><year>2002</year><volume>32</volume><fpage>35</fpage><lpage>41</lpage><!--PubMed citation query: 'Int J Gastrointest Cancer||32|35||bib15|'--><pub-id pub-id-type="pmid">12630768</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stemmler</surname><given-names>J</given-names></name><name><surname>Stieber</surname><given-names>P</given-names></name><name><surname>Szymala</surname><given-names>AM</given-names></name><name><surname>Schalhom</surname><given-names>A</given-names></name><name><surname>Schermuly</surname><given-names>MM</given-names></name><name><surname>Wilkowski</surname><given-names>R</given-names></name><name><surname>Helmberger</surname><given-names>T</given-names></name><name><surname>Lamerz</surname><given-names>R</given-names></name><name><surname>Stoffregen</surname><given-names>C</given-names></name><name><surname>Niebler</surname><given-names>K</given-names></name><name><surname>Garbrecht</surname><given-names>M</given-names></name><name><surname>Heinemann</surname><given-names>V</given-names></name></person-group><article-title>Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin</article-title><source>Onkologie</source><year>2003</year><volume>26</volume><fpage>462</fpage><lpage>467</lpage><!--PubMed citation query: 'Onkologie||26|462||bib16|'--><pub-id pub-id-type="pmid">14605463</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamasawa</surname><given-names>K</given-names></name><name><surname>Nio</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Itakura</surname><given-names>M</given-names></name></person-group><article-title>Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer</article-title><source>Clin Cancer Res</source><year>2002</year><volume>8</volume><fpage>2563</fpage><lpage>2569</lpage><!--PubMed citation query: 'Clin Cancer Res||8|2563||bib17|'--><pub-id pub-id-type="pmid">12171884</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ziske</surname><given-names>C</given-names></name><name><surname>Schlie</surname><given-names>C</given-names></name><name><surname>Gorschluter</surname><given-names>M</given-names></name><name><surname>Glasmacher</surname><given-names>A</given-names></name><name><surname>Mey</surname><given-names>U</given-names></name><name><surname>Strehl</surname><given-names>J</given-names></name><name><surname>Sauerbruch</surname><given-names>T</given-names></name><name><surname>Schmidt-Wolf</surname><given-names>IG</given-names></name></person-group><article-title>Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine</article-title><source>Br J Cancer</source><year>2003</year><volume>89</volume><fpage>1413</fpage><lpage>1417</lpage><!--PubMed citation query: 'Br J Cancer||89|1413||bib18|'--><pub-id pub-id-type="pmid">14562009</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Overall survival and pre-treatment CA19-9 level.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="93-6602760f1"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Baseline patient characteristics</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Characteristic</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Total patient cohort</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Patients with baseline CA19-9</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Patients with pre- and post-treatment CA19-9</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>n</italic></td><td align="char" valign="top" char="." charoff="50">218</td><td align="char" valign="top" char="." charoff="50">154</td><td align="char" valign="top" char="." charoff="50">88</td></tr><tr><td align="left" valign="top" charoff="50">Median age (range) (years)</td><td align="char" valign="top" char="." charoff="50">63 (28&#x02013;86)</td><td align="char" valign="top" char="." charoff="50">63 (28&#x02013;86)</td><td align="char" valign="top" char="." charoff="50">63 (42&#x02013;86)</td></tr><tr><td align="left" valign="top" charoff="50">Male (&#x00025;)</td><td align="char" valign="top" char="." charoff="50">62.8</td><td align="char" valign="top" char="." charoff="50">63.6</td><td align="char" valign="top" char="." charoff="50">62.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Disease extent</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Metastatic</td><td align="char" valign="top" char="." charoff="50">62.8</td><td align="char" valign="top" char="." charoff="50">66.2</td><td align="char" valign="top" char="." charoff="50">64.7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Locally advanced</td><td align="char" valign="top" char="." charoff="50">37.2</td><td align="char" valign="top" char="." charoff="50">33.8</td><td align="char" valign="top" char="." charoff="50">35.3</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Performance status</italic> (&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="char" valign="top" char="." charoff="50">12.8</td><td align="char" valign="top" char="." charoff="50">12.9</td><td align="char" valign="top" char="." charoff="50">17.0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="char" valign="top" char="." charoff="50">56.9</td><td align="char" valign="top" char="." charoff="50">62.3</td><td align="char" valign="top" char="." charoff="50">62.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="char" valign="top" char="." charoff="50">25.7</td><td align="char" valign="top" char="." charoff="50">24.7</td><td align="char" valign="top" char="." charoff="50">20.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="char" valign="top" char="." charoff="50">0.9</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Not documented</td><td align="char" valign="top" char="." charoff="50">3.7</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Chemotherapy received</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;None</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;PVI 5FU</td><td align="char" valign="top" char="." charoff="50">48</td><td align="char" valign="top" char="." charoff="50">51</td><td align="char" valign="top" char="." charoff="50">45.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;PVI 5FU&#x0002b;MMC</td><td align="char" valign="top" char="." charoff="50">33</td><td align="char" valign="top" char="." charoff="50">28</td><td align="char" valign="top" char="." charoff="50">21.6</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;GEM</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">8.5</td><td align="char" valign="top" char="." charoff="50">19.4</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;GEM&#x0002b;CAP</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">12.5</td><td align="char" valign="top" char="." charoff="50">12.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Other</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>PVI 5FU&#x0003d;protracted venous infused 5-fluorouracil, MMC&#x0003d;mitomycin C, GEM&#x0003d;gemcitabine, CAP&#x0003d;capecitabine.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Results of the multivariate analysis</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Variable</bold></th><th align="left" valign="top" charoff="50"><bold>Hazard ratio</bold></th><th align="left" valign="top" charoff="50"><bold>95&#x00025; confidence interval</bold></th><th align="left" valign="top" charoff="50"><bold><italic>P</italic>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>Baseline CA19-9</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Above <italic>vs</italic> below median</td><td align="char" valign="top" char="." charoff="50">1.84</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.31&#x02013;2.57</td><td align="char" valign="top" char="." charoff="50">0.0004</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>CA19-9 Response</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003c;20&#x00025; drop <italic>vs</italic> &#x02a7e;20&#x00025; drop</td><td align="char" valign="top" char="." charoff="50">1.95</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.11&#x02013;3.42</td><td align="char" valign="top" char="." charoff="50">0.019</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>PS</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2&#x02013;4 <italic>vs</italic> 0&#x02013;1</td><td align="char" valign="top" char="." charoff="50">1.75</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.19&#x02013;2.57</td><td align="char" valign="top" char="." charoff="50">0.004</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Sex</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male <italic>vs</italic> female</td><td align="char" valign="top" char="." charoff="50">1.52</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.06&#x02013;2.16</td><td align="char" valign="top" char="." charoff="50">0.02</td></tr></tbody></table></table-wrap></floats-wrap></article>


